AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39077475 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEDD measurements
Number of subjects: 33147
Study 39077494 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs
Number of subjects: 196
Study 39077494 — intervention group
Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 196
Study 39077519 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified GRACE scoring system (combining B-type natriuretic peptide precursor and traditional GRACE score)
Number of subjects: 4561
Study 39077519 — intervention group
Group type: COMPARATOR
Intervention: Traditional GRACE scoring system
Number of subjects: 4561
Study 39077543 — intervention group
Group type: EXPERIMENTAL
Intervention: eXtreme Gradient Boosting (XGBoost) model
Number of subjects: 400
Study 39077543 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline information
Number of subjects: 400
Study 39077543 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis and SHAP plot visualization methods
Number of subjects: 400
Study 39077558 — intervention group
Group type: EXPERIMENTAL
Intervention: High GAR group
Number of subjects: 14994
Study 39077558 — intervention group
Group type: COMPARATOR
Intervention: Low GAR group
Number of subjects: 14994
Study 39077587 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARIS algorithms for quantitative and localization analysis of thrombus burden
Number of subjects: 341
Study 39077655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 4394
Study 39077768 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 251
Study 39077768 — intervention group
Group type: COMPARATOR
Intervention: Control (nonrandomized groups)
Number of subjects: 251
Study 39077886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every four weeks
Number of subjects: 630
Study 39077886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study 39077886 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg every two weeks (BE OPTIMAL only)
Number of subjects: 630
Study 39077889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 130
Study 39077892 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical candidate intervention
Number of subjects: 0
Study 39077906 — intervention group
Group type: EXPERIMENTAL
Intervention: Itepekimab (300 mg q2w and q4w doses)
Number of subjects: 0
Study 39077906 — intervention group
Group type: EXPERIMENTAL
Intervention: Itepekimab alone and in combination with dupilumab
Number of subjects: 0
Study 39077906 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39077939 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D supplementation
Number of subjects: 2313
Study 39077939 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D + calcium supplementation
Number of subjects: 2313
Study 39077939 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D + calcium + other vitamins and minerals supplementation
Number of subjects: 2313
Study 39078289 — intervention group
Group type: EXPERIMENTAL
Intervention: Clo/ara-C (Clofarabine + Ara-C)
Number of subjects: 390
Study 39078289 — intervention group
Group type: COMPARATOR
Intervention: ACS10 score-based tailored induction (Clo/ara-C for low and LDAC for high-ACS10 score groups)
Number of subjects: 390
Study 39078403 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39078582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream applied twice daily for up to 52 weeks
Number of subjects: 652
Study 39078582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Number of subjects: 652
Study 39078584 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 0
Study 39078584 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 0
Study 39078584 — intervention group
Group type: COMPARATOR
Intervention: Dupilumab 300 mg
Number of subjects: 0
Study 39078682 — intervention group
Group type: EXPERIMENTAL
Intervention: DART assessment
Number of subjects: 78
Study 39078682 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted DART analysis
Number of subjects: 78
Study 39078682 — intervention group
Group type: EXPERIMENTAL
Intervention: System Usability Scale
Number of subjects: 78
Study 39078682 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapist triage
Number of subjects: 78
Study 39078687 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital somatosensory dance game training (two 30-minute sessions per week for 6 months)
Number of subjects: 60
Study 39078687 — intervention group
Group type: COMPARATOR
Intervention: Healthy aging education (control group)
Number of subjects: 60
Study 39078712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 0
Study 39078712 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 0
Study 39078826 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized food-derived resistant starches as an adjuvant therapy
Number of subjects: 42
Study 39078857 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated ventilation (INTELLiVENT-Adaptive Support Ventilation)
Number of subjects: 96
Study 39078857 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 96
Study 39078857 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated ventilation (INTELLiVENT-Adaptive Support Ventilation) in passive patients
Number of subjects: 96
Study 39078857 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation in passive patients
Number of subjects: 96
Study 39078857 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated ventilation (INTELLiVENT-Adaptive Support Ventilation) in active patients
Number of subjects: 96
Study 39078857 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation in active patients
Number of subjects: 96
Study 39079071 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) from participants with ALS Reversal, n = 22
Number of subjects: 22
Study 39079071 — intervention group
Group type: COMPARATOR
Intervention: Whole-genome sequencing (WGS) from the PGB primary cohort, n = 103
Number of subjects: 22
Study 39079071 — intervention group
Group type: COMPARATOR
Intervention: Whole-genome sequencing (WGS) from the Target ALS validation cohort, n = 140
Number of subjects: 22
Study 39079108 — intervention group
Group type: EXPERIMENTAL
Intervention: mPRISM (mobile app version of Promoting Resilience in Stress Management)
Number of subjects: 80
Study 39079108 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 80
Study 39079110 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory and promoted use of step tracker mobile app (10 weeks)
Number of subjects: 357
Study 39079110 — intervention group
Group type: COMPARATOR
Intervention: Nonmandatory and nonpromoted use of step tracker mobile app (10 weeks)
Number of subjects: 357
Study 39079111 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme Gradient Boosting (XGBoost) model for predicting all-cause in-hospital mortality.
Number of subjects: 30762
Study 39079111 — intervention group
Group type: COMPARATOR
Intervention: Global Registry of Acute Coronary Events (GRACE) model.
Number of subjects: 30762
Study 39079111 — intervention group
Group type: COMPARATOR
Intervention: TIMI model.
Number of subjects: 30762
Study 39079111 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost model validated on China PEACE cohort.
Number of subjects: 30762
Study 39079163 — intervention group
Group type: EXPERIMENTAL
Intervention: pegcetacoplan
Number of subjects: 25
Study 39079406 — intervention group
Group type: EXPERIMENTAL
Intervention: First-episode schizophrenia (FES) patients
Number of subjects: 75
Study 39079406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high-risk (UHR) individuals
Number of subjects: 75
Study 39079406 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 75
Study 39079612 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week intensive multi-component physical activity intervention combining a wearable physical activity tracker, social media peer support group, and individualized goal setting followed by a 24-week maintenance phase
Number of subjects: 384
Study 39079612 — intervention group
Group type: COMPARATOR
Intervention: Wearable physical activity tracker only (control group)
Number of subjects: 384
Study 39079614 — intervention group
Group type: EXPERIMENTAL
Intervention: FBT+ER (Family-based treatment with emotion regulation)
Number of subjects: 166
Study 39079614 — intervention group
Group type: COMPARATOR
Intervention: FBT (Standard Family-based treatment)
Number of subjects: 166
Study 39079754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear break-up time (TBUT)
Number of subjects: 0
Study 39079754 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer test
Number of subjects: 0
Study 39079754 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival staining
Number of subjects: 0
Study 39079754 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal staining
Number of subjects: 0
Study 39079754 — intervention group
Group type: EXPERIMENTAL
Intervention: Meibomian gland dysfunction (MGD)
Number of subjects: 0
Study 39079754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear osmolarity
Number of subjects: 0
Study 39079894 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept treatment
Number of subjects: 778
Study 39079894 — intervention group
Group type: COMPARATOR
Intervention: Active Conventional Treatment (ACT)
Number of subjects: 778
Study 39079894 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological treatments (including certolizumab pegol and tocilizumab)
Number of subjects: 778
Study 39079894 — intervention group
Group type: EXPERIMENTAL
Intervention: ACPA, RF and SE allele-related genotypes
Number of subjects: 778
Study 39079918 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval life events reported during follow-ups
Number of subjects: 330
Study 39079918 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress score (PSS-4)
Number of subjects: 330
Study 39079918 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval life events
Number of subjects: 330
Study 39079921 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative whole breast irradiation combined with regional lymph node irradiation (RNI) following breast-conserving surgery or chest wall irradiation with RNI after mastectomy
Number of subjects: 0
Study 39079925 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and usual care (n=125)
Number of subjects: 250
Study 39079925 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n=125)
Number of subjects: 250
Study 39079926 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated evidence-based physical therapy (I-EPT) with mindfulness-based interventions
Number of subjects: 90
Study 39079926 — intervention group
Group type: COMPARATOR
Intervention: High-intensity training (HighIT)
Number of subjects: 90
Study 39079926 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity training (LowIT)
Number of subjects: 90
Study 39079926 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 90
Study 39079927 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichoptic balanced binocular viewing (BBV) for 1 hour a day for 16 weeks
Number of subjects: 32
Study 39079927 — intervention group
Group type: COMPARATOR
Intervention: Standard management (part-time occlusion or atropine blurring) for 16 weeks
Number of subjects: 32
Study 39079927 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichoptic balanced binocular viewing (BBV)
Number of subjects: 32
Study 39079927 — intervention group
Group type: COMPARATOR
Intervention: Standard management (part-time occlusion or atropine blurring)
Number of subjects: 32
Study 39079928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat
Number of subjects: 0
Study 39080091 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 1132
Study 39080091 — intervention group
Group type: COMPARATOR
Intervention: Non-oxaliplatin
Number of subjects: 1132
Study 39080094 — intervention group
Group type: EXPERIMENTAL
Intervention: Conners, CPT-3 d' T-score
Number of subjects: 44
Study 39080094 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-3 d' T-score ≥ 60 (clinically significant poor performance)
Number of subjects: 44
Study 39080094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory responsiveness profiles
Number of subjects: 44
Study 39080094 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on sleep, quality of life, anxiety, and depressive symptoms
Number of subjects: 44
Study 39080094 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall attention problems
Number of subjects: 44
Study 39080153 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg once daily
Number of subjects: 1686
Study 39080153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1686
Study 39080153 — intervention group
Group type: COMPARATOR
Intervention: Apremilast 30 mg twice daily
Number of subjects: 1686
Study 39080181 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapokibart 600 mg loading dose, then 300 mg every 2 weeks for 52 weeks
Number of subjects: 127
Study 39080350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dactinomycin and Vincristine (AV) chemotherapy
Number of subjects: 327
Study 39080350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dactinomycin and Vincristine (AV) chemotherapy for bilateral stage I patients
Number of subjects: 327
Study 39080350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephron-sparing surgery (NSS)
Number of subjects: 327
Study 39080350 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and renal function
Number of subjects: 327
Study 39080350 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall estimated 5y-EFS for BWT
Number of subjects: 327
Study 39080350 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall estimated 5y-EFS for unilateral WT and contralateral nephroblastomatosis
Number of subjects: 327
Study 39080350 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall estimated 5y-EFS for bilateral nephroblastomatosis
Number of subjects: 327
Study 39080364 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositionable self-expanding valves
Number of subjects: 0
Study 39080364 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning during TAVR
Number of subjects: 0
Study 39080380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffs Inflated group (CI group, n=30)
Number of subjects: 60
Study 39080380 — intervention group
Group type: COMPARATOR
Intervention: Cuffs Collapsed group (CC group, n=30)
Number of subjects: 60
Study 39080417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 25
Study 39080545 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 40
Study 39080545 — intervention group
Group type: COMPARATOR
Intervention: Thoracic Paravertebral Block (TPVB)
Number of subjects: 40
Study 39080666 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMS-H exoskeleton in assistance mode
Number of subjects: 41
Study 39080698 — intervention group
Group type: EXPERIMENTAL
Intervention: Early percutaneous screw fixation
Number of subjects: 68
Study 39080698 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (early mobilization under physiotherapy and analgesics)
Number of subjects: 68
Study 39080734 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided home exercise telehealth intervention
Number of subjects: 0
Study 39080734 — intervention group
Group type: COMPARATOR
Intervention: Center-based exercise intervention
Number of subjects: 0
Study 39080741 — intervention group
Group type: EXPERIMENTAL
Intervention: DLB patients
Number of subjects: 84
Study 39080741 — intervention group
Group type: COMPARATOR
Intervention: Healthy Elderly Controls
Number of subjects: 84
Study 39080741 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer's Disease patients
Number of subjects: 84
Study 39081141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Daily Occupational Performance (CO-OP) intervention, 12 sessions (2 sessions per week, 1 hour each, over 6 weeks)
Number of subjects: 30
Study 39081141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 30
Study 39081460 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior TBI
Number of subjects: 405
Study 39081460 — intervention group
Group type: COMPARATOR
Intervention: No prior TBI
Number of subjects: 405
Study 39081632 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 796
Study 39081632 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vaccination
Number of subjects: 796
Study 39081682 — intervention group
Group type: EXPERIMENTAL
Intervention: No-added-sugar ice cream
Number of subjects: 0
Study 39081682 — intervention group
Group type: COMPARATOR
Intervention: Conventional ice cream
Number of subjects: 0
Study 39081738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumasiran (36 months of treatment)
Number of subjects: 39
Study 39081738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 months of lumasiran treatment)
Number of subjects: 39
Study 39081738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumasiran treatment
Number of subjects: 39
Study 39081738 — intervention group
Group type: COMPARATOR
Intervention: Lumasiran and Placebo
Number of subjects: 39
Study 39081738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumasiran
Number of subjects: 39
Study 39081746 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional-adjusted model for predicting reduced kidney function
Number of subjects: 14180
Study 39081746 — intervention group
Group type: COMPARATOR
Intervention: UK model without regional adjustment
Number of subjects: 14180
Study 39081763 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly semaglutide
Number of subjects: 0
Study 39081763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39081837 — intervention group
Group type: EXPERIMENTAL
Intervention: SLBT (Single Leg Balance Test)
Number of subjects: 0
Study 39081837 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT (Sit-to-Stand Test)
Number of subjects: 0
Study 39081837 — intervention group
Group type: EXPERIMENTAL
Intervention: 30CST (30-Second Chair Stand Test)
Number of subjects: 0
Study 39081982 — intervention group
Group type: EXPERIMENTAL
Intervention: BPSDiary intervention
Number of subjects: 300
Study 39081982 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study 39082399 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (ARNI) therapy
Number of subjects: 63
Study 39082405 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-SMA (Shared Medical Appointments)
Number of subjects: 242
Study 39082405 — intervention group
Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 242
Study 39082405 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-SMA
Number of subjects: 242
Study 39082406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular polypill (2 Polycaps taken orally once a day for 12 months, containing aspirin 100mg, simvastatin 20mg, hydrochlorothiazide 12.5mg, ramipril 5mg, and atenolol 50mg)
Number of subjects: 148
Study 39082406 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard secondary prevention therapy)
Number of subjects: 148
Study 39082415 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma putrescine levels
Number of subjects: 3570
Study 39082415 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma spermidine and spermine levels
Number of subjects: 3570
Study 39082415 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome of death and major disability (modified Rankin Scale score≥3)
Number of subjects: 3570
Study 39082421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress testing
Number of subjects: 84
Study 39082421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological stress testing
Number of subjects: 84
Study 39082421 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise stress testing
Number of subjects: 84
Study 39082421 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter testing
Number of subjects: 84
Study 39082421 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological assessments
Number of subjects: 84
Study 39082426 — intervention group
Group type: EXPERIMENTAL
Intervention: MyStroke personalized educational platform
Number of subjects: 120
Study 39082426 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke education
Number of subjects: 120
Study 39082471 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 8706
Study 39082471 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blockers (ARB)
Number of subjects: 8706
Study 39082471 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors (ACEi)
Number of subjects: 8706
Study 39082471 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy, alpha-blockers, and mineralocorticoid receptor antagonists
Number of subjects: 8706
Study 39082668 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab (Ven-Obi)
Number of subjects: 432
Study 39082668 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil-obinutuzumab (Clb-Obi)
Number of subjects: 432
Study 39082675 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRV plus bevacizumab
Number of subjects: 0
Study 39082675 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 0
Study 39082730 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAO
Number of subjects: 1020
Study 39082735 — intervention group
Group type: EXPERIMENTAL
Intervention: V116
Number of subjects: 717
Study 39082803 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of meropenem
Number of subjects: 16
Study 39082803 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion (II) of meropenem
Number of subjects: 16
Study 39083005 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat WeQuit training program
Number of subjects: 1887
Study 39083005 — intervention group
Group type: COMPARATOR
Intervention: Control group (thanks messages)
Number of subjects: 1887